Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims are consistent with label concepts (intravesical gene therapy, IFNα2b mechanism, BCG-unresponsive high-risk NMIBC/CIS population), but several statements overgeneralize or conflict with label specifics: dosing frequency is incorrect ("once"/"single-dose" vs every 3 months), and the clinical goal/durable response wording omits key label qualifiers and timing.
Category Scores
Accurate Statements
Adstiladrin (rAdstilnacogene rexaparvovec) is a gene therapy given as a one-time treatment instilled into the bladder.
Route/formulation: label describes ADSTILADRIN as for intravesical instillation only (2.2) and sterile suspension for intravesical instillation (3). Note: label does not support the "one-time"/"single-dose" characterization (see contradictions/omissions).
Adstiladrin delivers a therapeutic gene intended to make bladder cells produce interferon alpha-2b.
Mechanism: designed to deliver a gene encoding human IFNα2b to bladder urothelium; transient local expression (12.1).
Interferon alpha-2b produced by bladder cells is intended to help the immune system recognize and attack cancer cells.
Mechanism states anti-tumor effects anticipated from IFNα2b expression; label does not explicitly mention "immune system recognize and attack cancer cells" (see unsupported/omission).
Adstiladrin provides durable cancer control in certain adults with high-risk, non–muscle-invasive bladder cancer who do not respond to or cannot tolerate Bacillus Calmetti-Guérin (BCG) therapy.
Indication: adult high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors (1). Label provided does not include "cannot tolerate BCG" wording (see omissions/unsupported).
Adstiladrin is intended for adults with high-risk, non–muscle-invasive bladder cancer that is BCG-unresponsive and/or BCG-intolerant.
Partially supported by label: adult high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors (1). "BCG-intolerant" is not supported by the provided label excerpt.
For that population, the clinical goal of Adstiladrin is to achieve meaningful, durable responses after BCG failure or inability to receive BCG.
General goal of treatment after BCG-unresponsive disease is consistent with the indication; however the provided label excerpts do not state "durable responses" or "inability to receive BCG" in the wording supplied.
Unsupported Statements
Interferon alpha-2b produced by bladder cells is intended to help the immune system recognize and attack cancer cells.
The label excerpt (12.1) states anti-tumor effects are anticipated, but does not explicitly describe the immune system "recognize and attack" cancer cells.
Adstiladrin provides an improved chance of getting certain bladder cancer under control.
The label excerpts provided do not use this phrasing ("improved chance"/"under control").
Adstiladrin provides durable cancer control in certain adults with high-risk, non–muscle-invasive bladder cancer who do not respond to or cannot tolerate Bacillus Calmetti-Guérin (BCG) therapy.
Label excerpt (1) supports BCG-unresponsive NMIBC population but does not support "cannot tolerate BCG" in the provided indication text; "durable cancer control" is not explicitly stated in supplied excerpts.
Adstiladrin’s single-dose intravesical schedule contrasts with some standard intravesical therapies that involve repeated administrations over time.
The label excerpts provided do not make comparative claims about other intravesical therapies.
Administering Adstiladrin once via bladder instillation avoids long series of intravesical treatments that some patients may require with other approaches.
The label excerpts provided do not make comparative claims about other approaches requiring long series of treatments.
Adstiladrin is designed to be administered once via bladder instillation rather than repeated BCG-like dosing.
The label excerpt (2.1 and 14) indicates dosing once every three months (not a single instillation) for up to 12 months.
Contradictions
High
AI Statement
Adstiladrin (rAdstilnacogene rexaparvovec) is a gene therapy given as a one-time treatment instilled into the bladder.
Label Reference
2 DOSAGE AND ADMINISTRATION (2.1) and 14 CLINICAL STUDIES: recommended dose is 75 mL instilled once every three (3) months (not one-time); clinical study up to four doses over 12 months.
High
AI Statement
Adstiladrin is administered as a single-dose intravesical instillation schedule.
Label Reference
2.1 and 14: instilled once every three months (up to 12 months/four doses).
High
AI Statement
Adstiladrin is designed to be administered once via bladder instillation rather than repeated BCG-like dosing.
Label Reference
2.1 and 14: dosing occurs once every three months (repeated dosing), not a single instillation.
Important Omissions
Dose frequency/treatment schedule: recommended 75 mL at 3 x 10^11 vp/mL instilled once every three (3) months (not a single instillation); up to 12 months/four doses in study (2.1, 14).
Importance:
High
Indication specificity: label provided restricts to adult patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors; provided claims include "BCG-intolerant" (not present in supplied indication text).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The most critical misalignment is dosing characterization as a single instillation, while the label excerpt specifies repeated instillations every three months. This could lead to incorrect regimen expectations and potentially under- or mismanagement of treatment timing relative to label instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect dosing description (single-dose/one-time instillation) and partial mismatch to label indication wording ("BCG-intolerant" not supported by provided label excerpt).
Suggested Improvement
Revise dosing claims to reflect label schedule: 75 mL at 3 x 10^11 vp/mL intravesical instillation once every three months, with anticipated up to four doses over 12 months (per provided excerpts). Align indication wording to label: high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors; avoid asserting "BCG-intolerant" unless supported by the full label.